Will Eli Lilly announce a new Phase 3 trial for Zepbound and Taltz by 31 October 2026?
Posted 2026-09-01 — 60 days before the deadline, stated before the outcome.
Eli Lilly is a pharmaceutical company that develops treatments for metabolic and autoimmune diseases. Zepbound and Taltz are distinct therapeutic agents approved for different indications, and clinical trials often investigate the safety and efficacy of combining such drugs.
The claim
By 2026-10-31, Eli Lilly will not publicly announce the initiation of a new Phase 3 clinical trial specifically designed to test the concomitant use of Zepbound and Taltz (ixekizumab) for the treatment of psoriasis or psoriatic arthritis, despite the release of 52-week data from the TOGETHER-PsO and TOGETHER-PsA Phase 3b trials.
Reasoning trace
- Linchpin: The broader equity market and technology sector do not experience a systemic correction or bear market that suppresses valuations regardless of individual company fundamentals (underpins 57 predictions)
- Eli Lilly's strategy relies on continuous capital appreciation driven by expanding product labels and acquisition activity; this prediction tests whether the 'growth-at-any-cost' assumption holds for pharmaceuticals in the GLP-1 space by checking if Lilly continues to aggressively expand Zepbound's clinical footprint into new therapeutic areas (psoriasis) to maintain valuation momentum, or if it halts such expansion due to market or regulatory caution.
Evidence so far
1 confirming · 0 denying signals · 8 verified · 5 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 17 times since mint (last on 2026-10-16) — 76% at mint → 83% today.
What to watch
- leading indicator Eli Lilly announces positive or efficacy/safety data from the completed 52-week TOGETHER-PsO and TOGETHER-PsA Phase 3b trials in a press release or investor communication observed
- leading indicator Eli Lilly publicly announces or files results from the TOGETHER-PsO and TOGETHER-PsA Phase 3b trials showing efficacy and safety data for the Zepbound-Taltz combination in psoriasis or psoriatic arthritis observed
- leading indicator Eli Lilly publicly releases or files the 52-week efficacy and safety data from the TOGETHER-PsO Phase 3b trial observed
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.